Australian antiviral developer Island Pharmaceuticals (ASX: ILA) has provided an update on its ongoing engagement with the US Food and Drug Administration regarding the clinical development of Galidesivir.
Biome Australia (ASX:BIO) reported record sales for the second quarter and first half of FY26, delivering continued strong growth despite seasonal headwinds.
Imugene (ASX:IMU), a clinical-stage immuno-oncology company, announced that Dr. Bradley Glover has resigned from his role as COO to focus on other business interests.
Dual-listed biotech Mesoblast (ASX:MSB) has announced that chair Jane Bell will retire from the role and continue as a non-executive director.
4DMedical (ASX:4DX), a leader in respiratory imaging technology, has appointed Julian Sutton as CFO and executive director.
AdAlta (ASX:1AD) and its cellular immunotherapy subsidiary, AdCella, have announced a major global collaboration with Shanghai Cell Therapy Group to co-develop the first-in-class CAR-T therapy, BZDS1901, for markets outside Greater China.
Neurizon Therapeutics (ASX:NUZ) provided an update on its lead investigational therapy for Amyotrophic Lateral Sclerosis, NUZ-001.
Arovella Therapeutics (ASX:ALA) has filed an Investigational New Drug application with the US Food and Drug Administration for ALA-10.
Mesoblast (ASX:MSB) has repaid its senior secured loan from Oaktree Capital Management and partially settled its subordinated royalty facility with NovaQuest Capital Management.
Memphasys (ASX:MEM) has secured CE Mark approval for its Felix automated sperm selection system under the EU Medical Device Regulation.
Enlitic (ASX:ENL) has secured commitments for a capital raise of $8 million through the issuance of secured convertible notes to a group of sophisticated investors.
Adherium (ASX:ADR) exceeded its key commercial milestones for calendar year 2025, with total device shipments surpassing 4,666 units.
-640x360.png&w=3840&q=75)
